

# Corey S Cutler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1786416/publications.pdf>

Version: 2024-02-01

270  
papers

24,105  
citations

8159

76  
h-index

8138

148  
g-index

278  
all docs

278  
docs citations

278  
times ranked

16054  
citing authors

#	ARTICLE	IF	CITATIONS
1	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160.	1.7	10
2	Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant. <i>Blood Advances</i> , 2022, 6, 181-188.	2.5	15
3	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. <i>Blood Advances</i> , 2022, 6, 2183-2194.	2.5	12
4	Impact of conditioning regimen intensity on the outcomes of peripheral Tâ€cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic Tâ€cell lymphoma patients undergoing allogeneic transplant. <i>British Journal of Haematology</i> , 2022, 197, 212-222.	1.2	6
5	Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	48
6	Yin and Yang of Psychological Health in the Cancer Experience: Does Positive Psychology Have a Role?. <i>Journal of Clinical Oncology</i> , 2022, 40, 2402-2407.	0.8	12
7	Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 406.e1-406.e6.	0.6	4
8	A Review of Oral Chronic Graft-Versus-Host Disease: Considerations for dental hygiene practice.. <i>Journal of Dental Hygiene: JDH / American Dental Hygienists' Association</i> , 2022, 96, 6-17.	0.1	0
9	Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 508.e1-508.e8.	0.6	6
10	Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 419-425.	0.6	2
11	Peer support in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT): a qualitative study. <i>Bone Marrow Transplantation</i> , 2022, 57, 1277-1286.	1.3	4
12	Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 426-445.	0.6	16
13	Topical sirolimus for management of refractory oral chronic graftâ€versusâ€host disease. <i>Oral Diseases</i> , 2021, 27, 1451-1454.	1.5	2
14	Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. <i>Leukemia</i> , 2021, 35, 1166-1175.	3.3	5
15	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1006-1012.	1.3	15
16	Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2021, 5, 352-364.	2.5	58
17	COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. <i>Blood Advances</i> , 2021, 5, 861-871.	2.5	23
18	Use of Prescription Sialogogues for Management of Xerostomia in Chronic Graft-versus-Host-Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 480.e1-480.e5.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. <i>Blood Advances</i> , 2021, 5, 975-983.	2.5	27
20	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021, 137, 3212-3217.	0.6	24
21	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	0.6	24
22	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	1.3	6
23	A positive psychology intervention to promote health outcomes in hematopoietic stem cell transplantation: the PATH proof-of-concept trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 2276-2279.	1.3	14
24	The clinical and functional effects of <i>TERT</i> variants in myelodysplastic syndrome. <i>Blood</i> , 2021, 138, 898-911.	0.6	27
25	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021, 39, 3328-3339.	0.8	72
26	Treating Inflammation and Fibrosis in Chronic GVHD: Two Birds, One ROCK. <i>Journal of Clinical Oncology</i> , 2021, 39, 1942-1945.	0.8	0
27	Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. <i>Blood</i> , 2021, 138, 2278-2289.	0.6	124
28	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 545-557.	0.6	72
29	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. <i>Haematologica</i> , 2021, 106, 3219-3222.	1.7	15
30	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 632-641.	0.6	21
31	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 729-737.	0.6	29
32	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021, 5, 4549-4559.	2.5	8
33	Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. <i>Blood Advances</i> , 2021, 5, 5140-5149.	2.5	21
34	Disseminated varicella-zoster virus infections following messenger RNA-based COVID-19 vaccination. <i>JAAD Case Reports</i> , 2021, 17, 126-129.	0.4	11
35	Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. <i>Blood Advances</i> , 2021, 5, 4278-4284.	2.5	36
36	Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 990.e1-990.e7.	0.6	16

#	ARTICLE	IF	CITATIONS
37	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. Transplantation and Cellular Therapy, 2021, 27, 817-835.	0.6	62
38	Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease. Blood, 2021, 138, 264-264.	0.6	3
39	Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease. Blood, 2021, 138, 2891-2891.	0.6	0
40	Long-Term Utilization Patterns of Topical Therapy and Clinical Outcomes of Oral Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, 373-379.	2.0	4
41	Disability Related to Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, 772-777.	2.0	16
42	Incidence, Predictors, and Outcomes of Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 529-539.	2.0	14
43	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome. JAMA Oncology, 2020, 6, 486.	3.4	39
44	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	2.5	18
45	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Advances, 2020, 4, 4113-4123.	2.5	22
46	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood, 2020, 136, 3070-3081.	0.6	25
47	In response to the American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Advances, 2020, 4, 5431-5432.	2.5	1
48	Oral health in allogeneic hematopoietic stem cells transplantation survivors. Bone Marrow Transplantation, 2020, 55, 2211-2214.	1.3	3
49	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood, 2020, 135, 2182-2191.	0.6	62
50	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	2.5	63
51	BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Advances, 2020, 4, 1881-1893.	2.5	16
52	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood, 2020, 135, 28-40.	0.6	14
53	Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. Journal of Clinical Investigation, 2020, 130, 4624-4636.	3.9	55
54	Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213). Blood, 2020, 136, 45-46.	0.6	11

#	ARTICLE	IF	CITATIONS
55	Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab. <i>Blood</i> , 2020, 136, 10-11.	0.6	1
56	Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
57	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 137-144.	2.0	36
58	The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2468-2473.	2.0	4
59	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. <i>Clinical Immunology</i> , 2019, 207, 18-23.	1.4	10
60	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2002-2007.	2.0	64
61	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials) Tj ETQq1 1 0.784314 rgBT /Overlock	2.0	15
62	Targeting PI3K $\hat{\imath}$ function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019, 19, 1820-1830.	2.6	9
63	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. <i>Blood Advances</i> , 2019, 3, 2550-2561.	2.5	44
64	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	2.5	89
65	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019, 3, 2199-2204.	2.5	52
66	Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2019, 3, 4136-4146.	2.5	26
67	Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. <i>Blood Advances</i> , 2019, 3, 969-979.	2.5	32
68	The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 279-286.	2.0	6
69	Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 451-458.	2.0	19
70	Machine learning reveals chronic graft-versus-host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies. <i>Haematologica</i> , 2019, 104, 189-196.	1.7	44
71	Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 599-605.	2.0	20
72	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2019, 133, 94-99.	0.6	21

#	ARTICLE	IF	CITATIONS
73	Economic and Practical Considerations in the Treatment of Oral Mucosal Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1748-1753.	2.0	9
74	Î±1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. <i>Blood</i> , 2018, 131, 1372-1379.	0.6	81
75	Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 393-399.	2.0	24
76	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888.	2.5	27
77	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. <i>Blood Advances</i> , 2018, 2, 1022-1031.	2.5	13
78	Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2164-2165.	2.0	3
79	A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. <i>Haematologica</i> , 2018, 103, 1915-1924.	1.7	34
80	Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2344-2353.	2.0	37
81	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem-Cell Transplantation: A Post-Hoc Analysis of a Randomized Controlled Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate (BMT CTN 0402). <i>Blood</i> , 2018, 132, 2110-2110.	0.6	1
82	A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Blood</i> , 2018, 132, 705-705.	0.6	10
83	Incidence and Predictors of Hepatic Veno-Occlusive Disease after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 3376-3376.	0.6	0
84	Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2018, 132, 817-817.	0.6	0
85	Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 882-896.	2.0	117
86	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017, 129, 2186-2197.	0.6	156
87	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 376, 536-547.	13.9	586
88	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	0.6	278
89	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 360-367.	0.6	52
90	A multicenter, retrospective, case-cohort study of the epidemiology and risk factors for <i>Clostridium difficile</i> infection among cord blood transplant recipients. <i>Transplant Infectious Disease</i> , 2017, 19, e12728.	0.7	19

#	ARTICLE	IF	CITATIONS
91	Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017, 102, 1185-1191.	1.7	31
92	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 971-979.	2.0	16
93	Improved survival after acute graft-versus-host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	1.7	79
94	Mechanistic approaches for the prevention and treatment of chronic GVHD. <i>Blood</i> , 2017, 129, 22-29.	0.6	98
95	Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. <i>Blood</i> , 2017, 129, 162-170.	0.6	75
96	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. <i>Cytotherapy</i> , 2017, 19, 272-284.	0.3	13
97	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017, 130, 2243-2250.	0.6	352
98	Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome – not because we can, but because we should. <i>Haematologica</i> , 2017, 102, 1970-1971.	1.7	9
99	Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 2889-2899.	0.6	17
100	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 126-133.	2.0	10
101	Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 103-112.	2.0	4
102	Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. <i>Blood Advances</i> , 2017, 1, 2269-2279.	2.5	16
103	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. <i>JCI Insight</i> , 2017, 2, .	2.3	53
104	Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. <i>JCI Insight</i> , 2016, 1, e89278.	2.3	126
105	The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. <i>British Journal of Haematology</i> , 2016, 173, 96-104.	1.2	53
106	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014.	2.0	45
107	A novel TERC CR4/CR5 domain mutation causes telomere disease via decreased TERT binding. <i>Blood</i> , 2016, 128, 2089-2092.	0.6	7
108	Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34 <sup>+</sup> cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016, 101, 499-505.	1.7	43



#	ARTICLE	IF	CITATIONS
109	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.	0.6	43
110	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. <i>Blood</i> , 2016, 127, 2144-2154.	0.6	145
111	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	0.8	61
112	Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. <i>Blood</i> , 2016, 127, 646-657.	0.6	145
113	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 130-137.	0.6	176
114	An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2084-2091.	2.0	16
115	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 1251-1259.	1.7	27
116	Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation. <i>JAMA Oncology</i> , 2016, 2, 1583.	3.4	110
117	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. <i>Blood</i> , 2016, 127, 2489-2497.	0.6	92
118	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2016, 375, 143-153.	13.9	488
119	Biomarker Panel for Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 2583-2590.	0.8	118
120	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 449-455.	2.0	113
121	Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 910-918.	2.0	32
122	Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402. <i>Blood</i> , 2016, 128, 63-63.	0.6	0
123	Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation: A Phase II Randomized Controlled Trial. <i>Blood</i> , 2016, 128, 508-508.	0.6	3
124	BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 3425-3425.	0.6	0
125	Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 667-667.	0.6	4
126	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 4085-4094.	0.6	101



#	ARTICLE	IF	CITATIONS
127	Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. <i>Haematologica</i> , 2015, 100, 1222-1227.	1.7	24
128	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1776-1782.	2.0	13
129	Reprint of: B Cells in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S11-S18.	2.0	4
130	Mammalian Target of Rapamycin Inhibitor-associated Stomatitis in Hematopoietic Stem Cell Transplantation Patients Receiving Sirolimus Prophylaxis for Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 503-508.	2.0	21
131	A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1907-1913.	2.0	27
132	Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 873-880.	2.0	56
133	Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 640-645.	2.0	23
134	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1343-1359.	2.0	105
135	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
136	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 389-401.e1.	2.0	2,636
137	B Cells in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 16-23.	2.0	86
138	Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age. <i>Blood</i> , 2015, 126, 193-193.	0.6	11
139	Outcomes of Grades II-IV Acute Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: How Much Progress Was Achieved?. <i>Blood</i> , 2015, 126, 3132-3132.	0.6	1
140	IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. <i>PLoS ONE</i> , 2015, 10, e0132564.	1.1	22
141	Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD). <i>Blood</i> , 2015, 126, 1930-1930.	0.6	2
142	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4867-4876.	3.9	173
143	Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 77-81.	0.9	10
144	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1499-1508.	1.7	15

#	ARTICLE	IF	CITATIONS
145	Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 2691-2698.	0.8	359
146	Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1566-1572.	2.0	24
147	A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1737-1743.	2.0	48
148	Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 668-675.	2.0	45
149	Outcomes and management strategies for graft failure after umbilical cord blood transplantation. <i>American Journal of Hematology</i> , 2014, 89, 1097-1101.	2.0	16
150	Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1262-1273.	2.0	176
151	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
152	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014, 123, 3988-3998.	0.6	179
153	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. <i>Blood</i> , 2014, 124, 1372-1377.	0.6	178
154	Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 804-811.	2.0	18
155	Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 2662-2670.	0.8	265
156	Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease. <i>Science Translational Medicine</i> , 2013, 5, 179ra43.	5.8	401
157	Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. <i>Blood</i> , 2013, 122, 3074-3081.	0.6	280
158	Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). <i>Blood</i> , 2013, 122, 1974-1982.	0.6	92
159	Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. <i>Blood</i> , 2013, 122, 1510-1517.	0.6	104
160	Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients. <i>Blood</i> , 2013, 122, 695-695.	0.6	3
161	Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intensity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis. <i>Blood</i> , 2013, 122, 2093-2093.	0.6	10
162	Reconstitution Of EBV-Specific Immunity In Adult Recipients Of Double Cord Blood Transplantation Depends On SCF and IL-7 Levels and Maintenance Of a Diverse TCR Repertoire. <i>Blood</i> , 2013, 122, 3302-3302.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Bortezomib-Based Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 3202-3208.	0.8	135
164	Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. <i>New England Journal of Medicine</i> , 2012, 367, 1487-1496.	13.9	762
165	Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients. <i>Science Translational Medicine</i> , 2012, 4, 117ra7.	5.8	312
166	Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 253-265.	1.1	40
167	A disease risk index for patients undergoing allogeneic stem cell transplantation. <i>Blood</i> , 2012, 120, 905-913.	0.6	310
168	Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. <i>Blood</i> , 2012, 120, 2545-2552.	0.6	101
169	Poor Agreement between Clinician Response Ratings and Calculated Response Measures in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1649-1655.	2.0	22
170	Transplantation for MDS in the Elderly: More Evidence, or More Bias?. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1320-1321.	2.0	5
171	B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. <i>Blood</i> , 2012, 120, 2529-2536.	0.6	126
172	GVHD Prevention: An Ounce Is Better Than a Pound. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S17-S26.	2.0	10
173	First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1150-1163.	2.0	506
174	Improving outcomes in umbilical cord blood transplantation: State of the art. <i>Blood Reviews</i> , 2012, 26, 241-246.	2.8	32
175	Clinical Benefit of Response in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1517-1524.	2.0	47
176	Risk factors for acute GVHD and survival after hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 296-307.	0.6	559
177	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 311-311.	0.6	3
178	Gastrointestinal and Hepatic Involvement in Chronic Gvhd: An Analysis From the Chronic Gvhd Consortium. <i>Blood</i> , 2012, 120, 1940-1940.	0.6	0
179	Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012, 120, 1892-1892.	0.6	0
180	Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3069-3069.	0.6	5

#	ARTICLE	IF	CITATIONS
181	Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2011, 365, 2055-2066.	13.9	996
182	Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 852-860.	2.0	98
183	Generic Immunosuppressants in Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 285-290.	2.0	12
184	Use of Matched Unrelated Donors Compared with Matched Related Donors Is Associated with Lower Relapse and Superior Progression-Free Survival after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1196-1204.	2.0	57
185	Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1796-1803.	2.0	123
186	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. <i>Blood</i> , 2011, 117, 4651-4657.	0.6	319
187	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. <i>Blood</i> , 2011, 117, 6714-6720.	0.6	128
188	Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. <i>Blood</i> , 2011, 118, 5021-5030.	0.6	44
189	Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. <i>Blood</i> , 2011, 117, 2275-2283.	0.6	115
190	Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. <i>Blood</i> , 2011, 118, 282-288.	0.6	549
191	Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. <i>Blood</i> , 2011, 118, 6691-6697.	0.6	180
192	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. <i>Blood</i> , 2011, 118, 4242-4249.	0.6	196
193	Rituximab for prevention and treatment of graft-versus-host disease. <i>International Journal of Hematology</i> , 2011, 93, 578-585.	0.7	44
194	Review of Stem-Cell Transplantation for Myelodysplastic Syndromes in Older Patients in the Context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome Emanating From the Centers for Medicare and Medicaid Services. <i>Journal of Clinical Oncology</i> , 2011, 29, 566-572.	0.8	31
195	A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS. <i>Blood</i> , 2011, 118, 115-115.	0.6	16
196	Does Iron Overload Really Matter in Stem Cell Transplantation?. <i>Blood</i> , 2011, 118, 3029-3029.	0.6	0
197	A Disease and Stage Risk Grouping System for Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 327-327.	0.6	0
198	Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update. <i>Current Opinion in Hematology</i> , 2010, 17, 500-504.	1.2	39

#	ARTICLE	IF	CITATIONS
199	Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndrome. Hematology American Society of Hematology Education Program, 2010, 2010, 325-329.	0.9	21
200	Should Methotrexate plus Calcineurin Inhibitors Be Considered Standard of Care for Prophylaxis of acute Graft-versus-Host Disease?. Biology of Blood and Marrow Transplantation, 2010, 16, S18-S27.	2.0	48
201	Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced Age. Biology of Blood and Marrow Transplantation, 2010, 16, 792-800.	2.0	76
202	Donor-Derived Second Hematologic Malignancies after Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 1025-1031.	2.0	47
203	Prediction of Venous Occlusive Disease Using Biomarkers of Endothelial Injury. Biology of Blood and Marrow Transplantation, 2010, 16, 1180-1185.	2.0	85
204	Patient Selection for Transplantation in the Myelodysplastic Syndromes. Hematology/Oncology Clinics of North America, 2010, 24, 469-476.	0.9	7
205	Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. Journal of Clinical Investigation, 2010, 120, 1479-1493.	3.9	212
206	Acute Graft Versus Host Disease: Prophylaxis. , 2010, , 565-576.		0
207	Reply to J. Mehta. Journal of Clinical Oncology, 2009, 27, e139-e140.	0.8	0
208	Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. British Journal of Haematology, 2009, 145, 816-824.	1.2	66
209	High-resolution HLA matching in double umbilical cord blood reduced-intensity transplantation in adults. Transfusion, 2009, 49, 995-1002.	0.8	34
210	Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease Prophylaxis after Reduced-Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 844-850.	2.0	55
211	Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation, 2009, 15, 1005-1013.	2.0	116
212	Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood, 2009, 113, 3865-3874.	0.6	285
213	Current and novel therapies in acute GVHD. Best Practice and Research in Clinical Haematology, 2008, 21, 223-237.	0.7	37
214	Costs of Allogeneic Hematopoietic Cell Transplantation with High-Dose Regimens. Biology of Blood and Marrow Transplantation, 2008, 14, 197-207.	2.0	95
215	Sirolimus, Tacrolimus, and Low-Dose Methotrexate as Graft-versus-Host Disease Prophylaxis in Related and Unrelated Donor Reduced-Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 920-926.	2.0	50
216	Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning. Journal of Clinical Oncology, 2008, 26, 5767-5774.	0.8	105

#	ARTICLE	IF	CITATIONS
217	Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2008, 112, 4425-4431.	0.6	153
218	Novel Drugs for the Prevention and Treatment of Acute GVHD. <i>Current Pharmaceutical Design</i> , 2008, 14, 1962-1973.	0.9	15
219	Stem Cell Sources for Allogeneic Transplantation. , 2008, , 225-244.		0
220	Development of CMV-SPECIFIC Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of NaïVE CD8+ T Cells. <i>Blood</i> , 2008, 112, 1167-1167.	0.6	0
221	High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease. <i>Clinical Cancer Research</i> , 2007, 13, 6107-6114.	3.2	238
222	Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. <i>Blood</i> , 2007, 109, 3108-3114.	0.6	177
223	Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. <i>Blood</i> , 2007, 109, 4586-4588.	0.6	395
224	Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. <i>Blood</i> , 2007, 110, 490-500.	0.6	136
225	Double Unrelated Reduced-Intensity Umbilical Cord Blood Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 82-89.	2.0	294
226	Prior Therapy with Rituximab Correlates with Less Acute Graft-Versus-Host Disease and Better Survival in B-Cell Lymphoma Patients Who Received Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).. <i>Blood</i> , 2007, 110, 1063-1063.	0.6	2
227	Chronic GVHD Is Associated with a BAFF Driven BCR-Activated B Cell Repertoire.. <i>Blood</i> , 2007, 110, 166-166.	0.6	1
228	Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis.. <i>Blood</i> , 2007, 110, 2016-2016.	0.6	1
229	Tacrolimus and Sirolimus without Methotrexate as Acute GVHD Prophylaxis after Matched Related Donor Reduced Intensity Conditioning (RIC) Stem Cell Transplantation (SCT).. <i>Blood</i> , 2007, 110, 3046-3046.	0.6	1
230	Non-Myeloablative Allogeneic Transplantation for Hodgkinâ€™s and Non-Hodgkinâ€™s Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. <i>Blood</i> , 2007, 110, 3041-3041.	0.6	0
231	Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 552-559.	2.0	102
232	Impact of Conditioning Regimen Intensity on Outcome of Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1047-1055.	2.0	181
233	Chronic graft-versus-host disease. <i>Current Opinion in Oncology</i> , 2006, 18, 126-131.	1.1	38
234	The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era. <i>Current Hematologic Malignancy Reports</i> , 2006, 1, 160-167.	1.2	2



#	ARTICLE	IF	CITATIONS
235	Rituximab for steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2006, 108, 756-762.	0.6	422
236	Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. <i>Blood</i> , 2006, 108, 259-259.	0.6	1
237	Risk of HHV6-Associated Post-Transplant Acute Limbic Encephalitis (PALE) after Umbilical Cord Blood Stem Cell Transplantation: A Cohort Analysis.. <i>Blood</i> , 2006, 108, 2929-2929.	0.6	1
238	Effects of Cord Blood Cell Subset Populations in the Development of the Dominant Cord Blood Unit in Non-Myeloablative Sequential Double Cord Blood Transplantation (DCBT).. <i>Blood</i> , 2006, 108, 3148-3148.	0.6	1
239	GM-CSF Secreting Leukemia Cell Vaccinations after Allogeneic Reduced-Intensity Peripheral Blood Stem Cell Transplantation (SCT) for Advanced Myelodysplastic Syndrome (MDS) or Refractory Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2006, 108, 3680-3680.	0.6	1
240	Prognostic Impact of Elevated Serum Ferritin in Patients Undergoing Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 595-595.	0.6	2
241	Costs of Complications after Allogeneic Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 2977-2977.	0.6	0
242	Long-Term Outcome of Methotrexate-Free GVHD Prophylaxis Using Sirolimus and Tacrolimus in Matched Related (MRD) and Unrelated Donor (URD) Peripheral Blood Stem Cell Transplantation (PBSCT).. <i>Blood</i> , 2006, 108, 757-757.	0.6	0
243	Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. <i>Blood</i> , 2005, 105, 1810-1814.	0.6	280
244	Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. <i>Blood</i> , 2005, 105, 2973-2978.	0.6	361
245	Mucositis after Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study of Methotrexate- and Non-Methotrexate-Containing Graft-versus-Host Disease Prophylaxis Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 383-388.	2.0	98
246	Sirolimus and Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 551-557.	2.0	153
247	An Overview of Hematopoietic Stem Cell Transplantation. <i>Clinics in Chest Medicine</i> , 2005, 26, 517-527.	0.8	26
248	HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 835-835.	0.6	3
249	Sirolimus and Tacrolimus without Methotrexate as Graft-vs.-Host Disease Prophylaxis after Matched, Unrelated Peripheral Blood Stem Cell Transplantation: Excellent GVHD Control with Low Transplant-Related Morbidity and Mortality.. <i>Blood</i> , 2005, 106, 2051-2051.	0.6	0
250	Comparison of Methotrexate- Versus Sirolimus- Containing Graft-Versus-Host Disease Prophylaxis Regimens after Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 1797-1797.	0.6	0
251	Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 328-336.	2.0	136
252	Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. <i>Blood</i> , 2004, 104, 1559-1564.	0.6	193



#	ARTICLE	IF	CITATIONS
253	Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2004, 104, 1224-1226.	0.6	140
254	A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. <i>Blood</i> , 2004, 104, 579-585.	0.6	638
255	Stem Cell Sources. , 2004, , 337-356.		1
256	Sirolimus and Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 1834-1834.	0.6	2
257	Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.. <i>Blood</i> , 2004, 104, 2251-2251.	0.6	2
258	Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.. <i>Blood</i> , 2004, 104, 351-351.	0.6	3
259	Sirolimus, Tacrolimus and Reduced-Dose Methotrexate as Graft Versus Host Disease (GVHD) Prophylaxis after Non-Myeloablative Stem Cell Transplantation: Low Incidence of Acute GVHD Compared with Tacrolimus/Methotrexate or Cyclosporine/Prednisone.. <i>Blood</i> , 2004, 104, 730-730.	0.6	5
260	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. <i>Blood</i> , 2004, 104, 1227-1227.	0.6	0
261	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. <i>Blood</i> , 2004, 104, 185-185.	0.6	0
262	Allogeneic B Cell Response to H-Y Minor Histocompatibility Antigens after Donor Lymphocyte Infusion Correlates with Disease Response.. <i>Blood</i> , 2004, 104, 296-296.	0.6	0
263	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. <i>Blood</i> , 2004, 104, 300-300.	0.6	2
264	Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD.. <i>Blood</i> , 2004, 104, 3317-3317.	0.6	0
265	Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2003, 102, 1578-1582.	0.6	299
266	Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. <i>Blood</i> , 2003, 102, 1601-1605.	0.6	151
267	Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell Transplantation: A Little Methotrexate Goes a Long Way. <i>Journal of Clinical Oncology</i> , 2002, 20, 603-606.	0.8	6
268	Acute and Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell and Bone Marrow Transplantation: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2001, 19, 3685-3691.	0.8	396
269	Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review. <i>Stem Cells</i> , 2001, 19, 108-117.	1.4	89
270	Choroidal Metastases. <i>Journal of Clinical Oncology</i> , 1999, 17, 3358-3359.	0.8	5